Other drugs used to treat ATL include Kyowa Kirin's amti-CCR4 antibody Poteligeo (mogamulizumab ... "As the first dual inhibitor of EZH1 and EZH2 to receive regulatory approval anywhere in ...

Germinal center B-cell–like diffuse large B-cell lymphomas (GCB-DLBCLs) show dependence on DOT1L and EZH2, with combined targeting offering potential as an alternative differentiation-based therapy.